Help Therapeutics has developed HiCM388, China’s first cell therapy drug for heart attack recovery, now approved for clinical trials by the NMPA.

The achievement follows Help’s groundbreaking HiCM-188 therapy, the world’s first iPSC-derived cardiomyocyte treatment to receive dual approvals from both China and the U.S.

As clinical trials expand across Asia and North America, Airuipu continues to redefine how Chinese biotech innovations shape the future of global cell therapy.